45 results on '"Kasibante, John"'
Search Results
2. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
3. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
4. Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician’s perspective
5. Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal Meningitis
6. Role of cytokines in predicting one-year mortality in non-traumatic spinal cord injury (NTCSI) patients in Uganda
7. Diagnosis and management of cryptococcal meningitis in HIV-infected adults
8. 1490. Predictors of Early Mortality in HIV-associated Tuberculous Meningitis
9. Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial
10. Distal jejunal obstruction due to Cryptococcus neoformans and rifampicin-resistant Mycobacterium tuberculosis co-infection: A case report
11. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
12. 869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
13. Diagnostic and Prognostic Value of Cerebrospinal Fluid Lactate and Glucose in HIV-Associated Tuberculosis Meningitis
14. Therapeutic Lumbar Punctures in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?
15. Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort
16. Outpatient Cryptococcal Antigen Screening Is Associated With Favorable Baseline Characteristics and Improved Survival in Persons With Cryptococcal Meningitis in Uganda
17. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
18. Outpatient Cryptococcal Antigen Screening Is Associated With Favorable Baseline Characteristics and Improved Survival in Persons With Cryptococcal Meningitis in Uganda.
19. Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort
20. Open access, open education resources and open data in Uganda
21. Neurocognitive outcomes of HIV-associated tuberculous meningitis
22. Evaluation of the Initial 12 Months of a Routine Cryptococcal Antigen Screening Program in Reduction of HIV-Associated Cryptococcal Meningitis in Uganda
23. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults : A Phase II Open-Label Randomized Controlled Trial
24. COVID-19 and the HIV care continuum in Uganda: minimising collateral damage
25. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
26. Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis
27. Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
28. A Journey of Hope: giving research participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda
29. Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease
30. Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus–Associated Tuberculous Meningitis
31. High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)
32. COVID-19 and the HIV care continuum in Uganda: minimising collateral damage
33. Improving Tuberculous Meningitis Diagnostics - A Combined Host and Pathogen Classifier (5356)
34. Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis
35. High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)
36. Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus–Associated Tuberculous Meningitis.
37. Tobacco products use among secondary school students in Uganda
38. Open access, open education resources and open data in Uganda
39. CSF IMMUNE RESPONSE ASSOCIATED WITH FUNGAL BURDEN IN CRYPTOCOCCAL MENINGITIS.
40. CEREBROSPINAL FLUID PROTEIN CLINICAL IMPACT IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS.
41. Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis
42. Improving Tuberculous Meningitis Diagnostics - A Combined Host and Pathogen Classifier
43. Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal Meningitis.
44. Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort.
45. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.